期刊的影响因子--文章列表

期刊文章列表
Kai Yuan^1,2，Xiao Wang^1,2，Haojie Dong^1,2，Wenjian Min^1,2，Haiping Hao^1,2，Peng Yang^1,2（State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization，China Pharmaceutical University；Department of Medicinal Chemistry，School of Pharmacy，China Pharmaceutical University）.Selective inhibition of CDK4/6：A safe and effective strategy for developing anticancer drugs[J].Acta Pharmaceutica Sinica B,2021,第1期 Zhibin Yan¹，Dan Wang¹，Chunmei An¹，Hongjiao Xu²，Qian Zhao²，Ying Shi²，Nazi Song²，Bochuan Deng¹，Xiaomin Guo¹，Jing Rao¹，Lu Cheng¹，Bangzhi Zhang¹，Lingyun Mou¹，Wenle Yang¹，Xianxing Jiang²，Junqiu Xie¹（Key Laboratory of Preclinical Study for New Drugs of Gansu Province，School of Basic Medical Sciences &Research Unit of Peptide Science，Chinese Academy of Medical Sciences，2019RU066，Lanzhou University；School of Pharmaceutical Sciences，Sun Yat-sen University）.The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis[J].Acta Pharmaceutica Sinica B,2021,第1期 Xiaojie Chen¹，Jiafeng Zou¹，Ke Zhang¹，Jingjing Zhu¹，Yue Zhang¹，Zhihong Zhu¹，Hongyue Zheng²，Fanzhu Li¹，Ji-Gang Piao¹（College of Pharmaceutical Sciences，Zhejiang Chinese Medical University；Libraries of Zhejiang Chinese Medical University，Zhejiang Chinese Medical University）.Photothermal/matrix metalloproteinase-2 dual-responsive gelatin nanoparticles for breast cancer treatment[J].Acta Pharmaceutica Sinica B,2021,第1期 Hao Zengy，Lingling Wangy，Jiawei Zhang，Ting Pan，Yinghua Yu，Jingxia Lu，Ping Zhou，Hua Yang，Ping Li（State Key Laboratory of Natural Medicines，School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Activated PKB/GSK-3β synergizes with PKC-δ signaling in attenuating myocardial ischemia/reperfusion injury via potentiation of NRF2 activity：Therapeutic efficacy of dihydrotanshinone-Ⅰ[J].Acta Pharmaceutica Sinica B,2021,第1期 Shuang Zhou¹，Jinbo Li¹，Jiang Yu¹，Liyuan Yang¹，Xiao Kuang¹，Zhenjie Wang¹，Yingli Wang¹，Hongzhuo Liu¹，Guimei Lin²，Zhonggui He¹，Dan Liu³，Yongjun Wang¹（Wuya College of Innovation，Shenyang Pharmaceutical University；School of Pharmaceutical Science，Shandong University；Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education，Shenyang Pharmaceutical University）.A facile and universal method to achieve liposomal remote loading of non-ionizable drugs with outstanding safety profiles and therapeutic effect[J].Acta Pharmaceutica Sinica B,2021,第1期 Shun Zhang^1,2,3，Yan Zhao^2,4,5，Shuyuan Wang^2,3，Min Li^2,3，Yue Xu^2,3，Jianhua Ran⁶，Xiaoqiang Geng²，Jinzhao He^2,3，Jia Meng^2,3，Guangying Shao^2,3，Hong Zhou^2,3，Zemei Ge^2,4，Guangping Chen⁷，Runtao Li^2,4，Baoxue Yang^1,2,3（Department of Pharmacology，School of Basic Medical Sciences，Peking University；State Key Laboratory of Natural and Biomimetic Drugs，Peking University；Key Laboratory of Molecular Cardiovascular Sciences，Ministry of Education；School of Pharmaceutical Sciences，Peking University；College of Pharmacy，Inner Mongolia Medical University；Department of Anatomy and Neuroscience Center，Chongqing Medical University；Department of Physiology，Emory University School of Medicine）.Discovery of novel diarylamides as orally active diuretics targeting urea transporters[J].Acta Pharmaceutica Sinica B,2021,第1期 Bing Zhao¹，Xinhui Zhang¹，Tingting Yu¹，Ying Liu¹，Xiaoling Zhang¹，Yongfang Yao¹，Xuejian Feng¹，Hongmin Liu¹，Dequan Yu²，Liying Ma¹，Shangshang Qin¹（State Key Laboratory of Esophageal Cancer Prevention and Treament，Key Laboratory of Technology of Drug Preparation(Zhengzhou University)，Ministry of Education of China，Key Laboratory of Henan Province for Drug Quality and Evaluation，Institute of Pharmaceutical Research and School of Pharmaceutical Sciences，Zhengzhou University；State Key Laboratory of Bioactive Substance and Function of Natural Medicines，Institute of Materia Medica，Chinese Academy of Medical Sciences and Peking Union Medical College）.Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1(NDM-1) inhibitors against NDM-1 producing clinical isolates[J].Acta Pharmaceutica Sinica B,2021,第1期 Jinyang Li¹，Jiasheng Lu¹，Haiyan Guo¹，Jianfen Zhou¹，Songli Wang¹，Kuan Jiang¹，Zhilan Chai¹，Shengyu Yao¹，Xiaoyi Wang¹，Linwei Lu²，Cao Xie¹，Yi Chen³，Weiyue Lu^1,4,2,5（Department of Pharmaceutics，School of Pharmacy，Fudan University & Key Laboratory of Smart Drug Delivery(Fudan University)，Ministry of Education and PLA；The Institutes of Integrative Medicine of Fudan University；Chinese Academy of Sciences Shanghai Institute of Materia Medica；State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science，Institutes of Brain Science，Fudan University；Minhang Branch，Zhongshan Hospital and Institute of Fudan-Minghang Academic Health System，Minghang Hospital，Fudan University）.A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated[J].Acta Pharmaceutica Sinica B,2021,第1期 Xiaosa Changy，Dejuan Suny，Danfeng Shiy，Guan Wang，Yanmei Chen，Kai Zhang，Huidan Tan，Jie Liu，Bo Liu，Liang Ouyang（State Key Laboratory of Biotherapy and Cancer Center，West China Hospital，Collaborative Innovation Center of Biotherapy，Sichuan University）.Design, synthesis, and biological evaluation of quinazolin-4（3H）-one derivatives co-targeting poly （ADP-ribose） polymerase-1 and bromodomain containing protein 4 for breast cancer therapy[J].Acta Pharmaceutica Sinica B,2021,第1期 Jie Cheny，Yan Wangy，Di Zhao，Lingyuan Zhang，Weimin Zhang，Jiawen Fan，Jinting Li，Qimin Zhan（Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)，Laboratory of Molecular Oncology，Peking University Cancer Hospital & Institute）.Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma(ESCC)[J].Acta Pharmaceutica Sinica B,2021,第1期 Yu Sun¹，Jiahua Qian²（Department of Traditional Chinese Medicine and Ethnopharmaceuticals，Center for Drug Evaluation，National Medical Products Administration；Center for Drug Evaluation，National Medical Products Administration）.Botanical drug clinical trial：Common issues and future options[J].Acta Pharmaceutica Sinica B,2021,第1期 Zeqi Zhou¹，Xiangbin Wang²，Yankai Fu¹，Xiqing Zhang¹，Changxiao Liu³（Dynamiker Biotechnology Sub-Center，Beijing Key Laboratory for Mechanism Study and Precision Diagnosis of Invasive Fungal Diseases；Beijing Antai Zhiyuan Technology Co.，Ltd.；State Key Laboratory of Drug Delivery Technology and Pharmacokinetics，Tianjin Institute of Pharmaceutical Research）.Letter to the editor：Neutralizing antibodies for the treatment of COVID-19[J].Acta Pharmaceutica Sinica B,2021,第1期 Editoral Office of Acta Pharmaceutica Sinica.Information for Authors[J].药学学报(英文版),2021,第1期首页上一页 9 10 11 尾页共有11页，转到页

期刊文章列表